Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
docetaxel + vandetanib
- Development stage
- Phase 3
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Docetaxel + vandetanib is a combination therapy that pairs docetaxel, a taxane chemotherapeutic agent, with vandetanib, a tyrosine kinase inhibitor. Vandetanib inhibits vascular endothelial growth factor receptor 2 (VEGFR-2), epidermal growth factor receptor (EGFR), and RET tyrosine kinases. The combination alters the balance of proapoptotic and prosurvival proteins, potentially enhancing docetaxel-induced apoptosis in cancer cells. This combination has been studied in various cancer types including non-small cell lung cancer (NSCLC), prostate cancer, and urothelial cancer.
- Brand names
- Vandetanib + Taxotere
- Other names
- docetaxel + ZD6474
02
Targets
EGFR (Epidermal growth factor receptor)RET (Rearranged during transfection receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on docetaxel + vandetanib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on docetaxel + vandetanib.